Mapping the distribution of Loa loain Cameroon in support of the African Programme for Onchocerciasis Control
Open Access
- 6 August 2004
- journal article
- research article
- Published by Springer Nature in Filaria Journal
- Vol. 3 (1) , 7
- https://doi.org/10.1186/1475-2883-3-7
Abstract
Background: Loa loa has recently emerged as a filarial worm of significant public health importance as a consequence of its impact on the African Programme for Onchocerciasis Control (APOC). Severe, sometimes fatal, encephalopathic reactions to ivermectin (the drug of choice for onchocerciasis control) have occurred in some individuals with high Loa loa microfilarial counts. Since high density of Loa loa microfilariae is known to be associated with high prevalence rates, a distribution map of the latter may determine areas where severe reactions might occur. The aim of the study was to identify variables which were significantly associated with the presence of a Loa microfilaraemia in the subjects examined, and to develop a spatial model predicting the prevalence of the Loa microfilaraemia. Methods: Epidemiological data were collected from 14,225 individuals living in 94 villages in Cameroon, and analysed in conjunction with environmental data. A series of logistic regression models (multivariate analysis) was developed to describe variation in the prevalence of Loa loa microfilaraemia using individual level co-variates (age, sex, μl of blood taken for examination) and village level environmental co-variates (including altitude and satellite-derived vegetation indices). Results: A spatial model of Loa loa prevalence was created within a geographical information system. The model was then validated using an independent data set on Loa loa distribution. When considering both data sets as a whole, and a prevalence threshold of 20%, the sensitivity and the specificity of the model were 81.7 and 69.4%, respectively. Conclusions: The model developed has proven very useful in defining the areas at risk of post-ivermectin Loa-related severe adverse events. It is now routinely used by APOC when projects of community-directed treatment with ivermectin are examined.Keywords
This publication has 23 references indexed in Scilit:
- Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported casesFilaria Journal, 2003
- Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in CameroonFilaria Journal, 2003
- Effects of a 3-day regimen of albendazole (800 mg daily) onLoa loamicrofilaraemiaPathogens and Global Health, 2002
- Effect of a single dose (600 mg) of albendazole onLoa loamicrofilaraemiaParasite, 2002
- Encephalopathy following Loa loa treatment with albendazoleActa Tropica, 2001
- Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.The American Journal of Tropical Medicine and Hygiene, 1998
- Challenges for the future: loiasisPathogens and Global Health, 1998
- Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infectionThe Lancet, 1997
- Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areasParasitology Today, 1996
- Albendazole in Human Loiasis: Results of a Double-Blind, Placebo-Controlled TrialThe Journal of Infectious Diseases, 1993